{"schema_version":"secwatch.filing_event.v1","accession":"0001798749-24-000014","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.570032+00:00","generated_at":"2026-06-04T08:35:36.922571+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aerovate reports 2023 net loss $75.5M; Phase 2b topline data for AV-101 in PAH expected June 2024","bullets":["Cash, cash equivalents and short-term investments totaled $122.4M at Dec 31, 2023; cash runway expected into 2026.","Net loss for 2023 was $75.5M compared to $51.5M in 2022; R&D expenses rose to $64.2M from $38.6M.","Phase 2b portion of IMPAHCT trial enrolled 202 patients; topline data expected in June 2024.","First patient enrolled in Phase 3 portion of IMPAHCT in November 2023; over 120 clinical sites participating.","Board expanded with Habib Dable and Donald Santel; Dable appointed Chair in March 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001798749-24-000014","json":"https://secwatch.observer/filing/0001798749-24-000014.json","markdown":"https://secwatch.observer/filing/0001798749-24-000014.md","text":"https://secwatch.observer/filing/0001798749-24-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000179874924000014/0001798749-24-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000179874924000014/tmb-20240325x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:35:36.922571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"412d3fd74a7b783abae3b15b2e4bffa12d8056f9","claim":"Jade Biosciences, Inc. reported the year ended December 31, 2023 results: net income $75.5 million.","evidence_excerpt":"Net loss for the year ended December 31, 2023 was $75.5 million as compared to $51.5 million for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1798749/000179874924000014/0001798749-24-000014-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"$75.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}